Q3 2026 IPCA Laboratories Ltd Earnings Call Transcript
Key Points
- Ipca Laboratories Ltd (BOM:524494) reported a 12% growth in its domestic business for Q3 FY '26, outperforming the Indian Pharmaceutical Market (IPM) growth of 8.9%.
- The company's export formulation business showed a robust growth of 17% in Q3, contributing to a 6% growth over the nine-month period.
- Stand-alone EBITDA margin improved to 26.09% from 24.25% in the previous year, indicating better operational efficiency.
- The chronic segment of the domestic market grew by 15%, outpacing the IPM growth of 12%, showcasing strong performance in high-margin areas.
- The company has a healthy cash flow with over INR250 crores in the bank, and minimal capital expenditure plans, indicating strong financial health.
- Unichem's business faced challenges with a 2% growth due to loss of high-volume businesses in the US, impacting overall margins.
- The API business remained flat at INR317 crores for the quarter, indicating stagnation in this segment.
- The antimalarial segment declined by 21% in Q3, affecting the overall growth of the domestic business.
- Unichem's EBITDA margins are under pressure, currently at around 8%, with expectations of continued pressure for the next few quarters.
- The UK market faced significant pricing pressure, impacting margins, although a recovery is expected.
Ladies and gentlemen, good day and welcome to Ipca Laboratories earning conference call. Please stay on the line. The conference will begin shortly.
Ladies and gentlemen, good day, and welcome to Ipca Laboratories earnings conference call of Q3 and FY hosted by DAM Capital. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. Nitin Agarwal from DAM Capital. Thank you, and over to you.
Thank you, Kara. Good afternoon, everyone, and a very warm welcome to Ipca Lab's Q3 F '26 post-earnings call hosted by DAM Capital Advisors Limited. On the call today, we have representing Ipca Labs management, Mr. A.K. Jain, Managing Director; and Mr. Harish Kamath, Corporate Counsel and Company Secretary.
I will hand over the call to Mr. Jain to read the opening comments, and then we'll open the floor for questions. Please go ahead, sir.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
